Ipsen announced on March 9, 2026 the voluntary withdrawal of Tazverik from all markets effective immediately12
The Independent Data Monitoring Committee (IDMC) identified secondary hematologic malignancies (new blood cancers) in patients enrolled in the Phase Ib/III SYMPHONY-1 trial23
SYMPHONY-1 was evaluating Tazverik in combination with lenalidomide and rituximab as a second-line therapy for relapsed or refractory follicular lymphoma2
The IDMC determined that the risks of the combination regimen may outweigh potential benefits for patients23
Tazverik was approved by the FDA in 2020 under accelerated approval for treating follicular lymphoma and epithelioid sarcoma2
All patients enrolled in the SYMPHONY-1 trial are being transitioned to standard of care treatment with lenalidomide and rituximab alone3
Ipsen is discontinuing all active tazemetostat clinical trials and expanded access programs2
The drug had struggled with poor sales performance; Ipsen had initially forecasted 500 million euros in peak sales but reduced projections significantly1
The withdrawal is not expected to impact Ipsen's financial guidance12
Sources:
1. https://www.biopharmadive.com/news/ipsen-withdraw-tavzerik-lymphoma-malignancy-epizyme/814161/
2. https://www.ipsen.com/press-release/ipsen-voluntarily-withdraws-tazverik-tazemetostat-in-follicular-lymphoma-and-epithelioid-sarcoma-3251503/
3. https://www.pharmexec.com/view/ipsen-withdraws-tazverik-market-emerging-data-clinical-trial